Cytori Therapeutics, Inc. (USA) (NASDAQ:CYTX)

CAPS Rating: 2 out of 5

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.


Player Avatar zzlangerhans (99.77) Submitted: 7/30/2011 12:07:47 AM : Outperform Start Price: $4.36 CYTX Score: -56.85

Cytori is a very polarizing stock. Cheerleaders like Zacks point to positive data from clinical trials of adipose-derived regenerative cells in breast reconstruction, and a potential expansion of the technology to restore heart function after myocardial infarction. The ADVANCE pivotal trial in this indication is currently enrolling patients. Cytori's detrators, such as Feuerstein, point out that the data in breast reconstruction is subjective and uncontrolled, and has not led to any visible upward trend in Cytori's revenues. The company remains dependent on dilutive financings to continue their operations.

I've scored on Cytori in both directions, although I still find them too volatile and unpredictable to risk real money on. Today I saw the share price close to a one year low and I believe there's a substantial probability the stock will recover as ADVANCE gathers steam. Ultimately I'm on the negative side but I see more cycles of expansion and contraction in the future.

Member Avatar Kvedarna (99.50) Submitted: 4/12/2012 1:01:50 PM
Recs: 0

I wanted to go risk-on more than previously, so green thumbed a series of your bullish picks. Must admit to knowing very little about any of them. My thinking was these are high volatility names, they had seemed beaten down, and as a group they would lift. I would rather use the value you add than throw darts, although the idea of green thumbing every name in a screen had occurred to me. I have done that in the past, though with middling success....thx in advance, even for your caution that these may not work....EE

Featured Broker Partners